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Abstract
Background
Primaquine is the only licensed antimalarial for the radical cure of Plasmodium vivax infec-
tions. Many countries, however, do not administer primaquine due to fear of hemolysis in
those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In other settings, pri-
maquine is given without G6PD testing, putting patients at risk of hemolysis. New rapid diag-
nostic tests (RDTs) offer the opportunity to screen for G6PD deficiency prior to treatment
with primaquine. Here we assessed the cost-effectiveness of using G6PD RDTs on the
Thailand-Myanmar border and provide the model as an online tool for use in other settings.
Methods/Principal findings
Decision tree models for the management of P. vivax malaria evaluated the costs and dis-
ability-adjusted life-years (DALYs) associated with recurrences and primaquine-induced
hemolysis from a health care provider perspective. Screening with G6PD RDTs before pri-
maquine use was compared to (1) giving chloroquine alone and (2) giving primaquine with-
out screening. Data were taken from a recent study on the impact of primaquine on P. vivax
recurrences and a literature review. Compared to the use of chloroquine alone, the screen-
ing strategy had similar costs while averting 0.026 and 0.024 DALYs per primary infection in
males and females respectively. Compared to primaquine administered without screening,
the screening strategy provided modest cost savings while averting 0.011 and 0.004 DALYs
in males and females respectively. The probabilistic sensitivity analyses resulted in a
greater than 75% certainty that the screening strategy was cost-effective at a willingness to
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Conclusions/Significance
In this setting G6PD RDTs could avert DALYs by reducing recurrences and reducing hemo-
lytic risk in G6PD deficient patients at low costs or cost savings. The model results are lim-
ited by the paucity of data available in the literature for some parameter values, including the
mortality rates for both primaquine-induced hemolysis and P. vivax. The online model pro-
vides an opportunity to use different parameter estimates to examine the validity of these
findings in other settings.
Author summary
A single infection with Plasmodium vivax can cause multiple episodes of illness due to
dormant liver parasites called hypnozoites. Primaquine is the only drug currently available
to treat hypnozoites but is under-used because it can cause life-threatening red blood cell
damage in people who have an inherited condition called glucose-6-phosphate dehydro-
genase (G6PD) deficiency. In other locations, primaquine is given without testing for
G6PD deficiency, putting patients at risk of potentially fatal hemolysis. New rapid diag-
nostic tests provide the opportunity to screen for G6PD deficiency prior to giving patients
primaquine. Our study describes a cost-effectiveness analysis conducted using data gath-
ered from the Thailand-Myanmar border. Our results show that screening for G6PD defi-
ciency followed by primaquine treatment provided a few days of disability-free health per
patient treated. This was achieved for similar costs as not giving primaquine to anyone or
cost savings when compared to giving primaquine without screening. In addition to the
health gains provided to patients, the safe use of primaquine will be a critical tool to elimi-
nate malaria. We provide an interactive cost-effectiveness tool online that can be adapted
to other locations to examine the potential costs and benefits of using rapid diagnostic
tests for G6PD in different scenarios.
Introduction
Plasmodium vivax is an important public health concern, particularly in Asia and South Amer-
ica, where it is now responsible for the majority of malaria cases. While traditionally regarded
as a benign disease, P. vivax malaria has been associated with severe and fatal outcomes [1, 2].
As countries move toward malaria elimination and the overall incidence of malaria declines,
the proportion of cases that are due to P. vivax infections increases [3, 4]. A single infection of
P. vivax can lead to multiple relapses due to its ability to form dormant liver stage parasites
called hypnozoites. These relapses are indistinguishable from new infections and repeated epi-
sodes can lead to a cumulative risk of anemia and malnutrition [5, 6]. In short latency relapse
settings, the majority of P. vivax cases are thought to be due to relapses [7].
Primaquine is the only drug currently licensed for the radical cure of P. vivax; however, it
can cause severe hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD)
deficiency, a common genetic disorder [8] that is positively associated with P. vivax incidence
[9]. The prevalence of G6PD deficiency varies from less than 1% to more than 30%, with a
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mean of 8% in countries where malaria is endemic; equivalent to 350 million people worldwide
[10]. G6PD deficiency is largely asymptomatic until individuals are exposed to oxidative stress
from an external source, including certain drugs, such as primaquine, and foods, most notably
fava beans [9]. The degree of enzyme deficiency varies widely depending upon the genotypic
variant which varies with geographical region. A recent review found only 14 documented
deaths attributable to primaquine use [11]; however, fatalities may have gone unreported [12].
The WHO recommends that primaquine be used for the radical cure of P. vivax infected
patients who can be tested for G6PD deficiency [13]. The gold standard for diagnosing G6PD
deficiency is the spectrophotometric assay, a test that requires a laboratory setting and special-
ized staff [14, 15]. The Fluorescent Spot Test (FST), which is the most widely used assay for
G6PD deficiency, is easier to perform but requires basic laboratory equipment, electricity and
a cold chain, rendering it difficult to use in remote settings. Thus, routine testing for G6PD
deficiency prior to prescribing primaquine generally is not part of antimalarial policy in most
countries [16]. Recently, the CareStart G6PD (Access Bio, Somerset, NJ, USA) lateral flow
rapid diagnostic test (RDT) has become available for point of care testing. This phenotypic test
has high sensitivity for an enzyme activity cut off of 30% [17, 18]; hence false negative results
would rarely lead to a G6PD deficient individual receiving primaquine with an attendant risk
of hemolysis. Unlike the other G6PD RDT by BinaxNOW (Alere, Orlando, FL, USA), the Car-
eStart RDT can be used in settings where the temperature is above 25˚C, a common necessity
in P. vivax endemic settings[19, 20].
The availability of point of care G6PD tests is of clinical and public health importance so
that P. vivax patients have safe access to primaquine treatment for the prevention of relapses
and the resulting health complications [20]. Here we evaluate the cost-effectiveness of using
G6PD RDTs on the Thailand-Myanmar border and present our model as an interactive web
tool that can be adapted to other settings.
Methods
Base case analysis
A cost-effectiveness analysis [21] using a health care provider perspective was conducted with
decision tree models for P. vivax infections using R statistical software [22] over a 1 year time
horizon. The model was parameterized for the north-western border of Thailand with Myan-
mar (Tak Province), with the benefit of data on recurrences from a recent clinical trial at the
Shoklo Malaria Research Unit (SMRU), which provides free of charge care to migrants and
refugees [23] (S1 Appendix). In this population of migrants and refugees, the prevalence of
G6PD deficiency was documented to be 9–18% [24]. The most common genetic variant was
the Mahidol variant (88%) with Chinese-4, Viangchan, Ac¸ores, Seattle, and Mediterranean
variants also present [24]. Low, unstable P. vivax transmission is seen in this area [3] with a
frequent relapse pattern [25]. In recent years, the overall number of malaria cases has been
decreasing while the prevalence of P. vivax in the population has remained relatively stable at
9% [3]. Routine practice along the border is to administer 14 days of supervised therapy with
or without G6PD screening to patients able to attend the clinic; in practice this is a small pro-
portion of the patients.
The testing of G6PD status with CareStart G6PD RDT before administering primaquine
(“screening strategy”) was compared to a strategy in which no G6PD test is performed and pri-
maquine is not used at all (“chloroquine strategy”). In addition, the screening strategy is com-
pared with a strategy where primaquine is given to all patients without testing for G6PD
deficiency (“primaquine strategy”) (Table 1). The chloroquine strategy and primaquine strat-
egy were not directly compared to each other because (1) it is unlikely that in settings where
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the chloroquine strategy is used switching to the primaquine strategy would be a viable option
due to the evident concerns about safety and (2) it is unlikely that settings where the prima-
quine strategy is used would consider changing to the chloroquine strategy due to its inability
to achieve radical cure.
Recurrences were recorded over a one year time period in patients who were treated with
chloroquine alone, as compared with those who were treated with chloroquine plus 14 days of
supervised primaquine for each P. vivax episode (0.5 milligrams (mg)/kilogram (kg)/day) [23].
The relative risk of having at least one recurrence following primaquine treatment was 0.22 as
compared to those receiving chloroquine alone. For those who had at least one recurrence, the
mean number of recurrences was 3.54 in the chloroquine arm and 1.16 in the primaquine
arm. The model applied the inclusion criteria of the clinical trial, which was restricted to
patients who were six months and older, not pregnant and presenting with uncomplicated P.
vivax malaria [23]. The mean age in the clinical trial was 21 years; this was used for the disabil-
ity-adjusted life-year (DALY) calculations for years of life lost (S1 Appendix).
The analysis and results were completed separately for males (Fig 1) and females (Fig 2) to
account for their differences in risks and outcomes. Firstly, as pregnant females would not be
prescribed primaquine due to the unknown G6PD status of the fetus, the screening and prima-
quine strategies modeled the inclusion of a pregnancy test for all women of childbearing age
who were unaware that they were pregnant. Those who were identified or known to be preg-
nant would be treated with chloroquine only and would not have a G6PD RDT. Secondly,
since G6PD is an X-linked disorder, males who have deficiency are hemizygous while females
can be either homozygous or heterozygous with a range of G6PD expression levels. Accord-
ingly, G6PD deficiency was divided into two groups: severe (<30% enzyme activity) and
intermediate (30–69% enzyme activity) (S2 Appendix). Generally, only females can have inter-
mediate deficiency and the outcomes in this group were taken from heterozygotes. The G6PD
RDT with a cut off of 30% activity does not detect heterozygous females with intermediate
activity [16, 18]; accordingly, some women with intermediate deficiency who are identified as
G6PD normal with currently available RDTs could be at risk of severe hemolysis when pre-
scribed hemolytic drugs.
Table 1. Summary of key components of each strategy.
Chloroquine strategy Primaquine strategy Screening strategy
INITIAL VISIT
Treatment Chloroquine given to all. Chloroquine and supervised primaquine therapy (14
day) given to all. All individuals with severe G6PD
deficiency stop primaquine therapy early. Females
with intermediate G6PD deficiency who do not have
severe hemolysis complete primaquine therapy.
Chloroquine and supervised primaquine therapy (14
day) given to those who test G6PD normal.
Chloroquine and weekly primaquine given to those who
test G6PD abnormal. Individuals with severe G6PD
deficiency who are inadvertently given 14 day
primaquine will stop therapy early. Females with
intermediate G6PD deficiency who do not have severe
hemolysis complete primaquine therapy.
RECURRENCES (all costs and DALYs are weighted by the proportion of severe cases)
Costs Cost per recurrence. Cost per recurrence. Supervised primaquine (14 day)
for those who are G6PD normal.
Cost per recurrence. Includes G6PD RDT. Supervised
primaquine (14 day) for those who are G6PD true
normal. Supervised primaquine (8 weekly) for those
who test G6PD abnormal and false normal.
Effects All have the number of
recurrences for chloroquine
treatment.
G6PD abnormal individuals have the number of
recurrences for chloroquine treatment. G6PD normal
individuals have the number of recurrences for
primaquine treatment.
Those who test G6PD false normal have the number of
recurrences for chloroquine treatment. All other
individuals have the number of recurrences for
primaquine treatment.
https://doi.org/10.1371/journal.pntd.0005602.t001
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Table 2 shows the parameters used in the model. Both the screening and primaquine strate-
gies include the cost of supervised therapy in order to reflect the additional costs required for
the gains in effectiveness seen in the clinical trial. For the screening strategy, weekly supervised
primaquine therapy for 8 weeks was given to those who tested G6PD abnormal [26] and
the effectiveness was taken from the trial results for 14 day therapy (S1 Appendix). For each
recurrence, the cost and DALY value used were taken from clinical episodes, severe malaria
Fig 1. Model diagram of strategies for P. vivax treatment in males.
https://doi.org/10.1371/journal.pntd.0005602.g001
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Fig 2. Model diagram of strategies for P. vivax treatment in females.
https://doi.org/10.1371/journal.pntd.0005602.g002
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Table 2. Model parameters and sources. All costs are listed in 2014 United States Dollars.
Base case (low, high) Distribution
(Parameters*)
Sources
Proportion of males with severe G6PD deficiency 0.137 ± 50% Beta (13.50, 85.05) [24]
Proportion of females with severe G6PD deficiency 0.050 ± 50% Beta (15.17, 288.18) Females with <30% activity (S2 Appendix)
Proportion of females with intermediate G6PD activity 0.158 ± 50% Beta (12.96, 69.04) Females with 30–69% activity (S2 Appendix)
Sensitivity of CareStart G6PD RDT for severe
deficiency
0.99 (0.9 – 1.00) Beta (9.39, 0.09) [18] (Low range from [16])
Sensitivity of CareStart G6PD RDT for intermediate
deficiency
0.44 ± 50% Beta (7.97, 10.14) [18]
Specificity of CareStart G6PD RDT for males 0.99 (0.75 – 1.00) Beta (3.01, 0.03) [18] (Low range from [16])
Specificity of CareStart G6PD RDT for females 0.97 (0.68 to 0.99) Beta (2.59, 0.08) [18] (Low range from [16])
Proportion who have at least one recurrence in the
following year if treated with CQ
0.732 — [23] (S1 Appendix)
Relative risk of having at least one recurrence in the
following year if treated with CQ + PQ
0.219 (0.158 – 1) Lognormal (-1.52,
0.47)
[23] (S1 Appendix)
Mean number of recurrences in those treated with CQ
who have at least 1 recurrence
3.537 (1 – 8) Bootstrapped data [23] Each PSA iteration is the mean of 100
bootstrapped data points (S1 Appendix).
Mean number of recurrences in those treated with CQ
+ PQ who have at least 1 recurrence
1.156 (1 – 2) Bootstrapped data [23] Each PSA iteration is the mean of 100
bootstrapped data points (S1 Appendix).
Proportion who need a blood transfusion after taking
primaquine if have severe G6PD deficiency
0.109 (0.007 – 0.15) Beta (10.40, 85.01) [27]
Proportion who need a blood transfusion after taking
primaquine if have intermediate G6PD deficiency
0.005 (0.001 – 0.05) Beta (0.09, 18.72) [27, 28] Results for female heterozygotes
Proportion who need a transfusion due to hemolysis
but do not receive it
0.100 (0.010 – 0.150) Beta (8.77, 78.90) Assumption for both severe and intermediate
deficiency
Mortality due to not receiving a needed transfusion 0.100 (0.010 – 0.500) Beta (2.22, 19.95) Assumption for both severe and intermediate
deficiency
Proportion of females who are pregnant 0.11 ± 50% Beta (14.05, 113.65) Assumption
Proportion of females who need to take a pregnancy
test
0.50 ± 50% Beta (6.92, 6.92) Assumption. All women of childbearing age are
tested unless they disclose pregnancy
COSTS
CareStart G6PD RDT 1.75 (0.88 – 10.00) Gamma (0.38, 4.64) RDT (1.50) [29] and administration (0.25) [30]
Primaquine pill 0.06 ± 50% Gamma (24.71, 0.00) [31] 14 days of 30mg/day; 8 weeks of 45mg/
week. Assumed weight = 60kg.
One session of supervised primaquine therapy by a
community health worker
1.67 ± 50% Gamma (16.15, 0.10) [32] One-half day of work for a medium
accessible area with no incentives per
supervision
Initial episode and clinical P. vivax recurrence 7.86 ± 50% Gamma (16.10, 0.49) [33] Outpatient visit, excluding screening and
treatment costs
Severe P. vivax recurrence 196.22 (95% CI:
135.08 – 271.39)
Gamma (31.48, 6.23) [34] Inpatient visit for severe Plasmodium
falciparum
Hemolytic episode requiring transfusion 320.71 (166.03 –
401.53)
Gamma (32.55, 9.85) One unit of blood (25.31) [35] and 7 day inpatient
stay (295.40) [33]
Pregnancy test 0.10 ± 50% Gamma (16.10, 0.01) SMRU clinic records
DALYS
Proportion of P. vivax cases that are severe 0.020 (95% CI: 0.013
– 0.027)
Beta (31.41,
1539.05)
[2]
P. vivax mortality 0.0001 (95% CI:
0–0.001)
Beta (0.09, 929.01) Assumption
Life expectancy for males aged 20–24 in Myanmar 48.9 ± 20% Gamma (96.79, 0.51) [36]
Life expectancy for females aged 20–24 in Myanmar 52 ± 20% Gamma (96.79, 0.54) [36]
Length disability: clinical malaria 0.008 (0.003 – 0.019) Beta (3.27, 404.86) 3 days (range 1–7)
(Continued )
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episodes and episodes that resulted in death and weighted proportionally. The probability for
severe P. vivax was taken from a meta analysis of clinical studies using those with severe ane-
mia, but other symptoms due to severe P. vivax were not included [2].
The probability of having a hemolytic episode that requires a transfusion in individuals
with severe and intermediate G6PD deficiency treated with primaquine was taken from a
study of children treated with Dapsone in Africa [27]. While this population may be different
in terms of age and G6PD variant from those being treated with primaquine on the northwest-
ern border of Thailand with Myanmar, this was the best available data on transfusion risk. The
probability of hemolysis requiring transfusion for severe G6PD deficiency was taken from the
proportion of hemizygotes and homozygotes in the study while the probability for females
with intermediate deficiency was taken from the proportion of heterozygotes. It was assumed
that 10% of patients requiring a transfusion did not receive one; of those, 10% died as a result
of not receiving a transfusion. It was assumed that the decision to give a transfusion was made
by a physician and that the costs are included in the cost of transfusion.
Costs of commodities and service delivery were taken from Myanmar and Thailand and
supplemented by international sources when needed. Costs are reported in 2014 United States
Dollars (US$). The cost of supervised therapy was taken from data on annual costs of a com-
munity health worker in Myanmar [32], assuming one half-day of pay per observation. The
cost of hospitalization for a blood transfusion was included for severe hemolytic episodes
which did not lead to death. Table 1 describes the costs for recurrences.
The DALY weights were taken from the 2010 Global Burden of Disease Study [38]. These
weights were combined with life tables for Myanmar [36] and assumptions about the length of
illness to calculate the DALY burden for each strategy.
In instances where the screening strategy averted DALYs while costing more money the
incremental cost-effectiveness ratios (ICER) was calculated:
ICER ¼
Costs   Costb
DALYb   DALYs
Where Cost is the total cost of the strategy and DALYs is the total DALYs of the corresponding
strategy. While the gross domestic product per capita for Myanmar is approximately US$1200
[39], it has been argued that a lower willingness to pay threshold may be appropriate lower
Table 2. (Continued)
Base case (low, high) Distribution
(Parameters*)
Sources
Length disability: moderate anemia due to clinical
malaria
0.083 (0.04 – 0.17) Beta (5.39, 59.33) [37] 1 month (range 0.5 to 2)
Length disability: severe malaria 0.019 (0.008 – 0.027) Beta (16.91, 872.94) 7 days (range 3–10)
Length disability: severe anemia due to severe malaria
or hemolysis
0.250 (0.083 – 0.500) Beta (3.59, 10.76) 3 months (range 1–6)
Disability weight for clinical malaria 0.053 (0.033 – 0.081) Gamma (18.12,
0.003)
[38] infectious disease: moderate acute episode
Disability weight for moderate anemia due to clinical
malaria
0.058 (0.038 – 0.086) Gamma(21.70,
0.003)
[38]
Disability weight for severe malaria 0.210 (0.139 – 0.298) Gamma (26.50,
0.008)
[38] infectious disease: severe acute episode
Disability weight for severe anemia due to severe
malaria or hemolysis
0.164 (0.112 – 0.228) Gamma (30.37,
0.005)
[38]
* Parameters: Beta (alpha, beta), Lognormal (log (mean), log (standard deviation)) and Gamma (shape, scale).
https://doi.org/10.1371/journal.pntd.0005602.t002
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income countries [40]; consequently, a threshold of US$500 was chosen to reflect the resource
limitations of healthcare facilities serving migrant and refugee communities.
Sensitivity analyses
A one-way sensitivity analysis was conducted to examine the impact of parameter values on
the overall outcome. Low and high values were taken from 95% confidence intervals (CIs)
when available. When not available, the point estimate was varied by 50% and given wider
intervals when necessary to reflect the uncertainty (Table 2). Results that varied from the base
case by more than US$0.05 or 0.0002 DALYs averted were reported.
A probabilistic sensitivity analysis (PSA) was conducted to incorporate the uncertainty of
all parameters over 1000 sampling iterations using the parameter ranges used in the one-way
sensitivity analysis. Table 2 lists the distributions used in the PSA. The sum of squared differ-
ences was minimized from the specified ranges to produce the shape values for the beta and
gamma distributions and random numbers were generated from these distributions. The
mean number of recurrences for each iteration was calculated from 100 bootstrapped data
points that were randomly sampled from the data set with replacement (S1 Appendix). The
PSA produced a mean estimate and 95% credible intervals (CrIs) for the costs, DALYs and
incremental results.
A key concern is adherence to primaquine regimens by the patients as well as compliance
to guidelines by prescribers, which is collectively referred to as “adherence” here. In order to
account for this, a two-way sensitivity analysis examined the interplay of costs and benefits
depending on adherence to the primaquine strategy (whether primaquine was administered to
the patient and the full course taken) and screening strategy (whether a G6PD RDT plus prima-
quine was administered to the patient and the full course taken). This cohort analysis assumed
that at 0% adherence all individuals have a relative risk and mean number of recurrences equiv-
alent to receiving chloroquine only. The proportion of individuals in the population who are
adherent increases steadily until 100% adherence, which assumes that recurrences are equiva-
lent to the base case. Costs of supervised primaquine and G6PD screening were also varied
accordingly. Assumptions about adherence in individuals with G6PD deficiency who receive 14
day primaquine remain the same as the base case analysis.
Results
Comparison with the chloroquine strategy
Costs and DALYs for each strategy are shown in Table 3 and the cohort results are in Table 4.
On the Thailand-Myanmar border, the screening strategy averted more DALYs than the chlo-
roquine strategy: 0.026 for males and 0.024 for females. These gains were produced for similar
costs. The base case ICERs were US$6.3 and US$11.7 per DALY averted for males and females
respectively.
Fig 3 shows the results of the one-way sensitivity analysis in males (see S3 Appendix for all
results). The screening strategy always averted more DALYs than the chloroquine strategy
(S3C and S3D Appendix). Costs for the screening strategy were highest when radical cure had
a low impact on recurrences, when the costs of supervised therapy and the G6PD RDT were
increased, and also when the cost of a recurrence was decreased (S3A and S3B Appendix).
The only assumptions that made the screening strategy cost over US$500 per DALY averted
were lowering the number of recurrences after chloroquine to 1 (US$3678.7 in males and US
$3724.5 in females) and assuming the same relative risk of having at least one recurrence in
females (US$1223.6).
Cost effectiveness of using G6PD tests for the management of P. vivax
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The mean costs and DALYs and CrIs estimated by the PSA are shown in Table 4. The
screening strategy costing more than the chloroquine strategy with mean incremental cost of
US$0.8 (95%CrI: –17.4 to 19.7) and 0.026 DALYs averted (95%CrI: 0.007 to 0.117) per male
(Fig 4A). At a willingness to pay threshold of US$500, the screening strategy had an 81.2%
probability of being cost-effective (Fig 5A). The PSA resulted in a mean incremental cost of US
$0.75 (95%CrI: –15.0 to 20.0) with 0.023 DALYs averted (95%CrI: 0.006 to 0.122) per female
(Fig 4C) and a 77.6% probability of being cost-effective at a willingness to pay threshold of US
$500 (Fig 5C). The ICERs were US$31.3 per DALY averted for males and US$32.4 for females.
Table 3. Costs and disability adjusted life year (DALY) results over one year per primary episode treated in the base case analysis and probabilis-
tic sensitivity analysis (PSA). All costs are in 2014 United States Dollars.
Mean costs Mean DALYs
Base case PSA (95% CrI*) Base case PSA (95% CrI*)
Males
Chloroquine strategy 38.0 37.8 (24.6 to 55.5) 0.034 0.034 (0.009 to 0.137)
Primaquine strategy 45.3 45.8 (31.6 to 62.6) 0.019 0.019 (0.007 to 0.050)
Screening strategy 38.2 38.6 (25.2 to 55.3) 0.007 0.008 (0.003 to 0.018)
Females
Chloroquine strategy 38.0 38.3 (24.0 to 54.4) 0.034 0.034 (0.009 to 0.155)
Primaquine strategy 40.5 41.2 (28.3 to 59.0) 0.015 0.015 (0.006 to 0.040)
Screening strategy 38.3 39.1 (25.6 to 57.3) 0.011 0.011 (0.004 to 0.030)
* Credible interval.
https://doi.org/10.1371/journal.pntd.0005602.t003
Table 4. The table shows simulated outcomes for 1000 P. vivax malaria patients of undetermined G6PD status at attendance, if they were managed
according to each of three strategies (chloroquine, primaquine and screening) according to G6PD status, treatment given and the test result if
screened.
Initial treatment by G6PD status Males Females
Strategy Strategy
Chloroquine Primaquine Screening Chloroquine Primaquine Screening
G6PD normal who get primaquine and have no recurrences — 725 718 — 592 592
G6PD normal who get primaquine and have at least one recurrence — 138 137 — 113 113
G6PD normal who get chloroquine only and have no recurrences 231 — 2 212 — —
G6PD normal who get chloroquine only and have at least one
recurrence
632 — 6 580 — —
G6PD deficients* who get chloroquine only 137 — — 208 — —
G6PD deficients* who get weekly primaquine — — 136 — — 106
Severe G6PD deficients who get 14 day primaquine, do not complete
treatment but do not require a transfusion
— 122 1 — 40 0.40
Intermediate G6PD deficients who get 14 day primaquine and
complete treatment
— — — — 140 78
G6PD deficients* who get primaquine, hemolyze and receive a
required transfusion
— 13 0.13 — 5 0.40
G6PD deficients* who get primaquine, hemolyze, do not receive a
required transfusion and live
— 1 0.01 — 0.50 0.04
G6PD deficients* who get primaquine, hemolyze and die due to not
receiving a transfusion
— 0.15 0.001 — 0.06 0.004
Do not receive primaquine due to pregnancy — — — — 110 110
* For women, this includes both severe and intermediate G6PD deficiency.
https://doi.org/10.1371/journal.pntd.0005602.t004
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Comparison with the primaquine strategy
Again, the screening strategy resulted in better health outcomes in the base case with 0.011
DALYs averted in males and 0.004 in females (Table 3). The health gains in females were
more modest due to their overall lower probability of hemolysis requiring transfusion. In
addition, the screening strategy produced cost savings of US$7.1 and US$2.2 per male and
female initially treated, respectively (Table 3). The simulation output indicated that one
death due to hemolysis would be expected for every 6682 males and 15,994 non-pregnant
females treated using the primaquine strategy. This would be reduced to one death per
668,164 males and 201,198 non-pregnant females treated with the screening strategy
(Table 4).
The one-way sensitivity analysis showed that changes in the parameter values had a smaller
impact on the costs when comparing screening and primaquine strategies, especially for
females, and results that consistently averted DALYs (S3E–S3H Appendix). The parameters
related to mortality, the need for transfusion and the prevalence of G6PD deficiency having
the highest impact on DALY results (S3G and S3H Appendix). The screening strategy was cost
saving with the exception of raising the G6PD RDT cost to US$10.0, which caused an incre-
mental cost for the screening strategy of US$235.9 and US$1602.1 for males and females,
Fig 3. One-way sensitivity analysis results on costs and disability-adjusted life-years (DALYs) for the comparison of the screening strategy
with the chloroquine strategy in males. The ranges used are specified in Table 2. See S3 Appendix for all one-way sensitivity analysis results.
https://doi.org/10.1371/journal.pntd.0005602.g003
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respectively (S3E and S3F Appendix). The screening strategy remained cost saving even at low
levels of G6PD deficiency (7%).
The PSA showed a mean cost savings of US$7.3 (95%CrI: -15.4 to 3.4) and 0.012 DALYs
averted (95%CrI: 0.001 to 0.113) in males (Fig 4B), and a mean cost savings of US$2.2 (95%
CrI: –6.2 to 6.7) and 0.004 DALYs averted (95%CrI: 0.000 to 0.029) in females (Fig 4D). The
screening strategy had a 97.7% probability of being cost-effective for males at a willingness to
pay threshold of US$500.0 (Fig 5B). For females, the probability was 91.1% (Fig 5D). Table 3
shows the cost and DALY estimates from the PSA.
The two-way analysis (Fig 6) demonstrated that the screening strategy would be cost-effec-
tive in scenarios where it is used to maintain or increase the number of patients who are adher-
ent to their primaquine regimens. The impact of switching to the screening strategy was
slightly less in females due to the exclusion of pregnant women from primaquine treatment
and the low sensitivity of the G6PD RDT in women with intermediate G6PD deficiency.
Web-based application
Due to the extensive heterogeneity and parameter uncertainty around key parameter esti-
mates, notably relapse patterns [25], G6PD variants and prevalence [10] and costs, a web-
based interface was built using the R-Shiny application so that the model could be adapted to
other settings as need be. See website (https://malaria.shinyapps.io/g6pd_screening/).
Fig 4. Cost-effectiveness plane showing the incremental costs and DALYs averted from the probabilistic sensitivity analysis. Results show the
screening strategy versus: A) the chloroquine strategy in males, B) the primaquine strategy for males, C) the chloroquine strategy in females and D) the
primaquine strategy in females.
https://doi.org/10.1371/journal.pntd.0005602.g004
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Discussion
Point of care G6PD RDTs offer the opportunity for the safe uptake of primaquine for the pre-
vention of recurrences. Our findings suggest that on the Thailand-Myanmar border the use of
G6PD RDTs to identify patients with G6PD deficiency before supervised primaquine is likely
to provide significant health benefits (equivalent to between 1 and 9 days of perfect health)
compared to giving chloroquine alone or giving 14 day primaquine without G6PD testing.
Furthermore, the use of point of care G6PD RDTs will potentially save costs or, at most,
increase them moderately.
Primaquine is currently the only licensed hypnozonticidal drug, but healthcare profession-
als who treat P. vivax cases are often more concerned with avoiding the immediate risk of
hemolysis than with protecting the patient from the risks associated with future relapses. In
other settings, primaquine may be administered without G6PD testing, putting individuals
with G6PD deficiency at risk of severe hemolysis, although the degree of risk will depend upon
local G6PD variants and their prevalence. In the scenario presented, the use of G6PD RDTs
will save costs while averting DALYs compared to a policy in which primaquine is adminis-
tered without G6PD testing. While our results give a high probability of cost savings when
switching from the primaquine strategy to the screening strategy, this should not deter radical
cure without screening in settings where screening is unavailable as the primaquine strategy
averted more DALYs than the chloroquine strategy.
Fig 5. Cost-effectiveness acceptability curves. Results show the screening strategy versus: A) the chloroquine strategy in males, B) the primaquine
strategy for males, C) the chloroquine strategy in females and D) the primaquine strategy in females.
https://doi.org/10.1371/journal.pntd.0005602.g005
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Fig 6. Two-way sensitivity analysis results showing the impact of changes in the level of adherence to
primaquine regimens. Green represents disability-adjusted life-years (DALYs) averted by the screening strategy
for a cohort of 1000 individuals. For costs, yellow indicates increased costs and blue indicates cost savings for the
screening strategy for one individual. For net monetary benefit (NMB), purple indicates scenarios where the
screening strategy would be cost-effective at a threshold of US$500 (T) where NMB = T × ΔDALYs– ΔCosts.
https://doi.org/10.1371/journal.pntd.0005602.g006
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Our model is based on supervised primaquine therapy and hence our findings may not be
applicable to other settings where unsupervised primaquine is the norm and adherence to a
complete course of treatment and thus effectiveness may be low [41]. Our two-way analysis on
adherence (Fig 6) enabled comparison between settings with varying adherence and how this
impacts upon cost effectiveness. The screening strategy averts more DALYs than the prima-
quine strategy, even at relatively high primaquine strategy adherence and low screening strat-
egy adherence. Shorter drug courses, such as 7 day primaquine and tafenoquine, should
contribute to higher adherence levels and reduced costs for the primaquine and screening
strategies.
Overall, the screening strategy was less cost-effective in women as compared to men. This
reflects a greater proportion of women who are excluded from receiving primaquine due to
pregnancy and the lower risk of severe hemolysis in females with intermediate G6PD defi-
ciency. Since men represented 65% of patients in the trial that the recurrence data were derived
from (S1 Appendix), the overall cost-effectiveness estimates per person presenting with P.
vivax malaria would likely be closer to the results for males.
The cost-effectiveness of using G6PD RDTs is also dependent on the diagnostic accuracy of
the test. Our model draws on studies conducted on the Thailand-Myanmar border, which
demonstrated a high sensitivity in healthy volunteers. While other studies have shown similar
results [16, 17] in healthy volunteers, a recent study in Brazil found that the sensitivity of the
CareStart G6PD RDT dropped to 50% in patients with malaria compared to 80% in those who
did not [15]. A recent cost-effectiveness analysis of male patients with P. vivax malaria in Brazil
used a low sensitivity for the CareStart G6PD RDT (46%) but still found it to be more cost-
effective than both the BinaxNOW test and routine care; where the analysis also involved the
prescription of primaquine without having a G6PD test [42]. This study, however, used the
endpoints ‘adequately diagnosed case’ and ‘hospitalization avoided’ instead of DALYs. The
Brazilian population was given a 94% probability of hospitalization when primaquine was
given to G6PD deficient men. Our model differs in that we assume a lower rate of hospitaliza-
tion due to severe hemolysis. We also include results for both genders and report DALYs,
enabling comparisons with interventions for other diseases.
Our study has a number of limitations, mostly related to our model assumptions. The cost-
effectiveness of the screening strategy would be increased if it included the onward transmis-
sion of P. vivax or the longer term impact of repeated episodes, such as anemia, malnutrition
and all-cause mortality. This is particularly relevant in areas such as the Thailand-Myanmar
border where the estimated proportion of recurrences due to relapses is estimated to be 78%.
The cost-effectiveness may decrease if some individuals were not able to metabolize prima-
quine, if healthcare workers were not able to utilize G6PD RDTs or supervise primaquine regi-
mens, if the prevalence of G6PD deficiency in those presenting with P. vivax was lower to that
in the general population, if the diagnostic accuracy of the G6PD test were lower, if healthcare
facilities providing care for hemolytic episodes were not accessible or if the operational costs of
implementing a switch to the screening strategy were included. These parameter limitations
are similar to those highlighted in a recent review of the costs and cost-effectiveness of P. vivax
control and elimination [43].
Finally, our model is limited by the paucity of data available in the literature for some
parameter values, including the mortality rate for those who have a primaquine-induced
hemolytic episode requiring transfusion but do not receive them. Our assumptions of prima-
quine induced mortality were derived from previous risks of mortality in patients treated with
Dapsone in Africa and equated to a population risk of 1 in 6,682 administrations to males and
1 in 15,994 administrations in females. These risks are significantly higher than the risks docu-
mented in a previous review [11] but the screening strategy averted more DALYs than the
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primaquine strategy at a lower level of primaquine-induced mortality, though this is likely due
to the utilization of weekly primaquine by the screening strategy. Other variables, such as the
prevalence of G6PD deficiency will vary greatly depending on the epidemiological setting.
Whilst it would be beneficial to gather more robust parameter estimates on which to base
informed policy decisions, this should be tempered by the feasibility of gathering such data
and the potential benefits of implementing appropriate policies sooner, especially in the con-
text of elimination.
Although our model is relatively simple, it provides a useful starting point for policy makers
to compare the risks and benefits of using G6PD RDTs to enable the safe and effective use of
primaquine. To assist in this process we provide an online tool with which policy makers and
healthcare providers can vary the assumptions made in the model in keeping with local scenar-
ios and as additional data becomes available (https://malaria.shinyapps.io/g6pd_screening/).
As the only licensed antimalarial for the radical cure of P. vivax infections, primaquine will
be a critical tool for the elimination of all malaria [44] and for the health gains provided to
patients. The currently available G6PD RDTs can identify G6PD deficient males, making the
screening strategy an attractive option regardless of current practice. In situations where blood
transfusions are not accessible, further information may be required on the prevalence of
G6PD deficiency and associated risk of hemolysis in females with intermediate G6PD defi-
ciency who test normal by current G6PD RDT methods [28]. Despite the initial cost, point
of care RDTs avert DALYs by reducing recurrences while diminishing the hemolytic risk in
G6PD deficient patients.
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